Using mass-spectrometry—based phosphoproteomics, researchers at the Moffit Cancer Center have identified a mechanism by which BRAF/PTEN-null melanoma cells develop resistance to BRAF inhibitors.
Researchers at the Moffit Cancer Center have identified a mechanism by which BRAF/PTEN-null melanoma cells develop resistance to BRAF inhibitors. Using mass-spectrometry—based phosphoproteomics, the researchers found that treating these mutant-bearing melanoma cells with a BRAF inhibitor was associated with marked changes in fibronectin-based adhesion signaling that were PTEN dependent. These results are a step in the direction of developing combination therapies to prevent resistance and relapse in melanoma patients. Nearly 50% of melanoma patients harbor BRAF mutations and many of these patients relapse on these treatments. Identifying the mechanism of resistance is very important as a prevention strategy.
In their report in Oncogene, the authors present data showing an upregulation of the adhesion molecule fibronectin in a mouse melanoma model, with exposure to a BRAF inhibitor. The authors also conducted a phosphoproteomic analysis of patient tumor samples and identified a similar trend: those treated with a BRAF inhibitor had increased fibronectin expression and signaling, which was PTEN-dependent. Further, induction of fibronectin was associated with reduced overall survival due to a reduced response to the BRAF inhibitor.
The work has significant clinical implications with respect to developing novel combination strategies in melanoma.
Read more at ScienceDaily.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More